Literature DB >> 20880868

Progression of idiopathic pulmonary fibrosis: lessons from asymmetrical disease.

Colas Tcherakian1, Vincent Cottin, Pierre-Yves Brillet, Olivia Freynet, Nicolas Naggara, Zohra Carton, Jean-François Cordier, Michel Brauner, Dominique Valeyre, Hilario Nunes.   

Abstract

BACKGROUND: In idiopathic pulmonary fibrosis (IPF) the distribution and spatial-temporal progression of fibrotic changes may be influenced by general or locoregional conditions. From this perspective, patients with asymmetrical disease (AIPF) may be unique.
METHODS: This retrospective study included 32 patients (26 men, mean ± SD age 69 ± 7 years) with AIPF, as defined by an asymmetry ratio (most affected--least affected fibrosis score)/(most affected + least affected fibrosis score) >0.2. The global fibrosis score was the average of the right and left scores. Patients with AIPF were compared with 64 matched controls with symmetrical IPF.
RESULTS: Patients with AIPF did not differ from controls in global fibrosis score and forced vital capacity, but carbon monoxide transfer factor was less decreased (52 ± 19% vs 43 ± 13%, p=0.009). The rate of gastro-oesophageal reflux and acute exacerbations was significantly higher in patients with AIPF (62.5% vs 31.3%, p=0.006 and 46.9% vs 17.2%, p=0.004, respectively). In patients with AIPF the right side was more likely to be involved (62.5%); the median asymmetry ratio was 0.5 (range 0.24-1). Although the global fibrosis score worsened significantly in all 23 patients with AIPF with serial high-resolution CT scans (p<0.0001), pulmonary fibrosis remained asymmetrical in all except three. During follow-up, 15 patients with AIPF experienced 18 acute exacerbations. The first episode was virtually unilateral, occurring in the most affected lung in 10 patients (66.7%). Survival was similar between patients with AIPF and controls.
CONCLUSION: AIPF may be related to locoregional factors including gastro-oesophageal reflux which may be responsible for both disease expansion and the occurrence of acute exacerbations.

Entities:  

Mesh:

Year:  2010        PMID: 20880868     DOI: 10.1136/thx.2010.137190

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  22 in total

1.  Predictive factors for the effect of pirfenidone in idiopathic pulmonary fibrosis.

Authors:  Yasunori Ichimura; Kenji Tsushima; Takuma Matsumura; Kazutaka Yamagishi; Mitsuhiro Abe; Jun Ikari; Jiro Terada; Koichiro Tastumi
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

2.  Update in Interstitial Lung Disease 2016.

Authors:  Athol U Wells; Toby M Maher
Journal:  Am J Respir Crit Care Med       Date:  2017-07-15       Impact factor: 21.405

Review 3.  Acute Exacerbation of Idiopathic Pulmonary Fibrosis.

Authors:  Tomoo Kishaba
Journal:  Eurasian J Med       Date:  2017-10

4.  Single lobe disease in cases of advanced endemic goiter: a new phenotype.

Authors:  Omar Abdul Hameed Ali; Abdul Fatah Abdul Gadir
Journal:  Eur Thyroid J       Date:  2012-09-15

5.  Clinical characteristics in patients with asymmetric idiopathic pulmonary fibrosis.

Authors:  Sean J Callahan; Meng Xia; Susan Murray; Kevin R Flaherty
Journal:  Respir Med       Date:  2016-08-31       Impact factor: 3.415

6.  The Role of Gastroesophageal Reflux and Microaspiration in Idiopathic Pulmonary Fibrosis.

Authors:  Joyce S Lee
Journal:  Clin Pulm Med       Date:  2014-03-01

Review 7.  Idiopathic Pulmonary Fibrosis: Novel Concepts of Proton Pump Inhibitors as Antifibrotic Drugs.

Authors:  Yohannes T Ghebre; Ganesh Raghu
Journal:  Am J Respir Crit Care Med       Date:  2016-06-15       Impact factor: 21.405

Review 8.  Current and novel drug therapies for idiopathic pulmonary fibrosis.

Authors:  Huzaifa I Adamali; Toby M Maher
Journal:  Drug Des Devel Ther       Date:  2012-09-26       Impact factor: 4.162

9.  Asymmetrical Interstitial Lung Disease Suggested to Be Due to Hypoplasia of the Unilateral Pulmonary Artery: A Case Report with a 20-year Follow-up.

Authors:  Hiromi Tomioka; Hisanori Amimoto; Hiroshi Fujii; Eiji Katsuyama; Teruaki Okuno; Yoshinori Kawabata
Journal:  Intern Med       Date:  2020-11-16       Impact factor: 1.271

10.  Highlights of HRCT imaging in IPF.

Authors:  N Sverzellati
Journal:  Respir Res       Date:  2013-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.